Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 3/20 | 0.58 |
| ▸ | TP53 | P04637 | 3/20 | 0.58 |
| ▸ | CASP3 | P42574 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.51 |
| ▸ | MDM2 | Q00987 | 5/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL119442 | 1.00 | MDM4 (0.58) | MDM4TP53CASP3KMT2ASLC17A5 | |
| SCHEMBL29908070 | 1.00 | MDM4 (0.58) | MDM4TP53CASP3KMT2ASLC17A5 | |
| SCHEMBL2309917 | 1.00 | MDM4 (0.58) | MDM4TP53CASP3KMT2ASLC17A5 | |
| SCHEMBL29370319 | 1.00 | MDM4 (0.58) | MDM4TP53CASP3KMT2ASLC17A5 | |
| SCHEMBL29401991 | 1.00 | MDM4 (0.58) | MDM4TP53CASP3KMT2ASLC17A5 | |
| SCHEMBL30096349 | 0.92 | CASP3 (0.54) | MDM4TP53CASP3KMT2ASLC17A5 | |
| SCHEMBL29391787 | 0.91 | MDM4 (0.51) | MDM4TP53CASP3KMT2ASLC17A5 | |
| SCHEMBL27142935 | 0.91 | KMT2A (0.54) | MDM4TP53CASP3KMT2ASLC17A5 | |
| SCHEMBL27142932 | 0.91 | KMT2A (0.54) | MDM4TP53CASP3KMT2ASLC17A5 | |
| SCHEMBL20526769 | 0.90 | MDM4 (0.56) | MDM4TP53CASP3KMT2ASLC17A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3988538-A1 | MODIFIED HYDROPHOBIC AUXILIARY MATERIAL, PREPARATION METHOD THEREFOR AND USE THEREOF | Zhejiang Zhida Pharmaceutical Co., Ltd. (CN) | 2022-04-27 | — | — | EP | claimed |
| US-20220111055-A1 | MODIFIED HYDROPHOBIC EXCIPIENT AND PREPARATION METHOD THEREOF | ZHEJIANG ZHIDA PHARMACEUTICAL CO., LTD. (CN) | 2022-04-14 | — | — | US | claimed |
| WO-2020252713-A1 | MODIFIED HYDROPHOBIC AUXILIARY MATERIAL, PREPARATION METHOD THEREFOR AND USE THEREOF | 浙江智达药业有限公司 | 2020-12-24 | — | — | WO | claimed |
| US-12616676-B2 | Preparation method and use of modified hydrophobic excipient | ZHEJIANG ZHIDA PHARMACEUTICAL CO., LTD. (CN) | 2026-05-05 | — | — | US | disclosed |
| EP-3988538-B1 | MODIFIED HYDROPHOBIC AUXILIARY MATERIAL, PREPARATION METHOD THEREFOR AND USE THEREOF | ZHEJIANG ZHIDA PHARMACEUTICAL CO LTD (CN) | 2024-08-07 | — | — | EP | disclosed |
| US-20240226343-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. | 2024-07-11 | — | — | US | disclosed |
| EP-3988538-A1 | MODIFIED HYDROPHOBIC AUXILIARY MATERIAL, PREPARATION METHOD THEREFOR AND USE THEREOF | Zhejiang Zhida Pharmaceutical Co., Ltd. (CN) | 2022-04-27 | — | — | EP | disclosed |
| US-20220111056-A1 | DRUG-LOADED EMULSION | ZHEJIANG ZHIDA PHARMACEUTICAL CO., LTD. (CN) | 2022-04-14 | — | — | US | disclosed |
| US-20220110909-A1 | PREPARATION METHOD AND USE OF MODIFIED HYDROPHOBIC EXCIPIENT | ZHEJIANG ZHIDA PHARMACEUTICAL CO., LTD. (CN) | 2022-04-14 | — | — | US | disclosed |
| US-20220111055-A1 | MODIFIED HYDROPHOBIC EXCIPIENT AND PREPARATION METHOD THEREOF | ZHEJIANG ZHIDA PHARMACEUTICAL CO., LTD. (CN) | 2022-04-14 | — | — | US | disclosed |
| CN-109180533-A | A kind of N-9- fluorenylmethyloxycarbonyl-D-ASP -4- tert-butyl ester | 四川什邡市三高生化实业有限公司 | 2019-01-11 | — | — | CN | disclosed |
| US-8895231-B2 | Patterning process and resist composition | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2014-11-25 | — | — | US | disclosed |
| US-8895231-B2 | Patterning process and resist composition | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2014-11-25 | — | — | US | disclosed |
| US-20120058428-A1 | PATTERNING PROCESS AND RESIST COMPOSITION | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2012-03-08 | — | — | US | disclosed |
| US-20120058428-A1 | PATTERNING PROCESS AND RESIST COMPOSITION | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2012-03-08 | — | — | US | disclosed |
| US-20100210552-A1 | HUMAN GLUCAGON-LIKE PEPTIDE-1 MIMICS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY | 2010-08-19 | — | — | US | disclosed |
| US-20080051326-A1 | Antiinfective Lipopeptides | CUBIST PHARMACEUTICALS, INC. | 2008-02-28 | — | — | US | disclosed |
| US-20070287670-A1 | HUMAN GLUCAGON-LIKE PEPTIDE-1 MIMICS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY | 2007-12-13 | — | — | US | disclosed |
| EP-1814588-A2 | ANTIINFECTIVE LIPOPEPTIDES | Cubist Pharmaceuticals, Inc. (US) | 2007-08-08 | — | — | EP | disclosed |
| WO-2006110185-A2 | ANTIINFECTIVE LIPOPEPTIDES | CUBIST PHARMACEUTICALS, INC. (US) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12616676-B2 | Preparation method and use of modified hydrophobic excipient | CETP, LIPA, MTTP | MDM4 3741/4885TP53 1141/4885CASP3 1489/4885 |
| US-20070287670-A1 | HUMAN GLUCAGON-LIKE PEPTIDE-1 MIMICS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | GLP1R, IAPP, GIPR | MDM4 4381/4885TP53 3992/4885CASP3 513/4885 |
| US-20220111056-A1 | DRUG-LOADED EMULSION | SLC43A1, SLC7A1, CETP | MDM4 1435/4885TP53 1426/4885CASP3 2182/4885 |
| US-20100210552-A1 | HUMAN GLUCAGON-LIKE PEPTIDE-1 MIMICS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | GLP1R, IAPP, GIPR | MDM4 4381/4885TP53 3992/4885CASP3 513/4885 |
| US-20080051326-A1 | Antiinfective Lipopeptides | VIP, NGLY1, PREP | MDM4 1783/4885TP53 3112/4885CASP3 1022/4885 |
| US-20220111055-A1 | MODIFIED HYDROPHOBIC EXCIPIENT AND PREPARATION METHOD THEREOF | CETP, SLC43A1, SLC27A1 | MDM4 884/4885TP53 403/4885CASP3 2158/4885 |
| US-20240226343-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | NPY1R, NPY2R, NPY4R | MDM4 4491/4885TP53 517/4885CASP3 3087/4885 |
| US-20220110909-A1 | PREPARATION METHOD AND USE OF MODIFIED HYDROPHOBIC EXCIPIENT | ABCG2, CYP51A1, HACD3 | MDM4 4044/4885TP53 843/4885CASP3 700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.